AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23283502 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cobalamin concentration
Number of subjects: 0
Study 23283502 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma homocysteine concentration
Number of subjects: 0
Study 23283502 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma methylmalonic acid concentration
Number of subjects: 0
Study 23283502 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma folate concentration
Number of subjects: 0
Study 23284630 — intervention group
Group type: EXPERIMENTAL
Intervention: Support program
Number of subjects: 341
Study 23284630 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 341
Study 23285253 — intervention group
Group type: EXPERIMENTAL
Intervention: Boosted protease inhibitors (PI/r)
Number of subjects: 35
Study 23285253 — intervention group
Group type: COMPARATOR
Intervention: Cultured PBMCs from healthy donors
Number of subjects: 35
Study 23286772 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine
Number of subjects: 398
Study 23286772 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX and anti-TNF treatment
Number of subjects: 398
Study 23287785 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator
Number of subjects: 148
Study 23287861 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat at 30 mg 3 times a week (12 of 36 patients at 25 mg dose)
Number of subjects: 36
Study 23287861 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat
Number of subjects: 36
Study 23288240 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 23288588 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IFN-α therapy
Number of subjects: 175
Study 23288588 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy for coping with cancer (SECC)
Number of subjects: 175
Study 23288588 — intervention group
Group type: COMPARATOR
Intervention: Control (no IFN-α treatment)
Number of subjects: 175
Study 23289822 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily insulin detemir (Group A)
Number of subjects: 37
Study 23289822 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily insulin detemir (Group B)
Number of subjects: 37
Study 23290987 — intervention group
Group type: EXPERIMENTAL
Intervention: WOMAN-PRO instrument
Number of subjects: 65
Study 23291945 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of PHiD-CV
Number of subjects: 0
Study 23292236 — intervention group
Group type: EXPERIMENTAL
Intervention: BU pharmacokinetics (PKs) in patients with GSTM1 null genotype
Number of subjects: 69
Study 23292236 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTA1*A2 haplotype
Number of subjects: 69
Study 23292236 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-dosage effect
Number of subjects: 69
Study 23292236 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTA1 haplotypes
Number of subjects: 69
Study 23292236 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous individuals for haplotypes *B and *B1
Number of subjects: 69
Study 23292236 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTM1 null individuals older than 4 years
Number of subjects: 69
Study 23292756 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI, leptin, L/A ratio and CA 15-3
Number of subjects: 88
Study 23293169 — intervention group
Group type: EXPERIMENTAL
Intervention: Arstasis device
Number of subjects: 346
Study 23293330 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonalcoholic fatty liver disease (NAFLD)
Number of subjects: 0
Study 23294442 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (3-week inpatient PR)
Number of subjects: 138
Study 23294981 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained volunteer mealtime assistance
Number of subjects: 0
Study 23294981 — intervention group
Group type: COMPARATOR
Intervention: Control ward (no mealtime assistance)
Number of subjects: 0
Study 23294981 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative approaches (interviews and focus groups)
Number of subjects: 0
Study 23295604 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 23295790 — intervention group
Group type: EXPERIMENTAL
Intervention: R-INO (Inotuzumab ozogamicin plus rituximab)
Number of subjects: 118
Study 23298856 — intervention group
Group type: EXPERIMENTAL
Intervention: Second autologous hematopoietic cell transplantation (AHCT2)
Number of subjects: 187
Study 23299114 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotics (including macrolide antibiotics and penicillin V)
Number of subjects: 19938
Study 23299114 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tonsillitis
Number of subjects: 19938
Study 23299114 — intervention group
Group type: EXPERIMENTAL
Intervention: GPs with a prescription rate of 33.3% or higher
Number of subjects: 19938
Study 23299114 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing patient age
Number of subjects: 19938
Study 23299315 — intervention group
Group type: EXPERIMENTAL
Intervention: BiRd therapy (clarithromycin 500 mg twice daily, lenalidomide 25 mg daily on days 1 to 21 of a 28-day cycle, dexamethasone 40 mg weekly)
Number of subjects: 72
Study 23299315 — intervention group
Group type: EXPERIMENTAL
Intervention: BiRd therapy
Number of subjects: 72
Study 23299470 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution imaging techniques (AOSLO and SD-OCT)
Number of subjects: 11
Study 23299770 — intervention group
Group type: EXPERIMENTAL
Intervention: CF102 (1, 5, and 25 mg BID)
Number of subjects: 18
Study 23300829 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-DPA-714 PET imaging in ALS patients
Number of subjects: 10
Study 23300829 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (matched for age)
Number of subjects: 10
Study 23302513 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga classes (2 weekly 60-minute sessions for 32 weeks)
Number of subjects: 20
Study 23302513 — intervention group
Group type: EXPERIMENTAL
Intervention: Crescent pose
Number of subjects: 20
Study 23302513 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair pose
Number of subjects: 20
Study 23302513 — intervention group
Group type: EXPERIMENTAL
Intervention: Warrior II pose
Number of subjects: 20
Study 23302513 — intervention group
Group type: EXPERIMENTAL
Intervention: One-legged Balance pose
Number of subjects: 20
Study 23302513 — intervention group
Group type: EXPERIMENTAL
Intervention: Side Stretch pose
Number of subjects: 20
Study 23302513 — intervention group
Group type: EXPERIMENTAL
Intervention: Tree pose
Number of subjects: 20
Study 23303141 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation and surgery
Number of subjects: 153
Study 23303450 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6•IL-6Rα stimulation in HSFs
Number of subjects: 0
Study 23303450 — intervention group
Group type: EXPERIMENTAL
Intervention: STAT3 peptide inhibitor
Number of subjects: 0
Study 23303450 — intervention group
Group type: EXPERIMENTAL
Intervention: Knockdown of STAT3 by small interfering RNA
Number of subjects: 0
Study 23303450 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 23303512 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Burden of Illness Index for Depression (IBI-D) after 12-week citalopram treatment
Number of subjects: 2280
Study 23303512 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in IBI-D for patients with abnormal QOL and/or functioning
Number of subjects: 2280
Study 23303512 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in symptom severity (Quick Inventory of Depressive Symptomatology-Self Report)
Number of subjects: 2280
Study 23303852 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV+ patients
Number of subjects: 200
Study 23303852 — intervention group
Group type: COMPARATOR
Intervention: HIV- controls
Number of subjects: 200
Study 23305037 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride treatment (1 mg/d, titrated to 2 mg/d and 4 mg/d)
Number of subjects: 391
Study 23305037 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride treatment
Number of subjects: 391
Study 23305356 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with DM
Number of subjects: 2
Study 23305356 — intervention group
Group type: COMPARATOR
Intervention: Patients without DM
Number of subjects: 2
Study 23305356 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFα increase immediately after stent implantation
Number of subjects: 2
Study 23305475 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin analogues (insulin aspart, insulin detemir, biphasic insulin aspart 30)
Number of subjects: 10704
Study 23305732 — intervention group
Group type: EXPERIMENTAL
Intervention: PET imaging on day 7 of induction
Number of subjects: 302
Study 23305732 — intervention group
Group type: EXPERIMENTAL
Intervention: GEP high-risk designation
Number of subjects: 302
Study 23305732 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of > 3 focal lesions on day 7 PET follow-up
Number of subjects: 302
Study 23305860 — intervention group
Group type: EXPERIMENTAL
Intervention: AF knowledge scale
Number of subjects: 529
Study 23305955 — intervention group
Group type: EXPERIMENTAL
Intervention: NFKD
Number of subjects: 57
Study 23306324 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite Fabry disease diagnosed in 0.5% of patients (n=27)
Number of subjects: 5023
Study 23306324 — intervention group
Group type: EXPERIMENTAL
Intervention: Probable Fabry disease diagnosed in additional 18 patients
Number of subjects: 5023
Study 23306324 — intervention group
Group type: EXPERIMENTAL
Intervention: Silent infarcts on MRI
Number of subjects: 5023
Study 23306324 — intervention group
Group type: EXPERIMENTAL
Intervention: Common causes of ischemic stroke
Number of subjects: 5023
Study 23306324 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of classical risk factors
Number of subjects: 5023
Study 23306540 — intervention group
Group type: EXPERIMENTAL
Intervention: Any history of donor smoking
Number of subjects: 1255
Study 23306540 — intervention group
Group type: EXPERIMENTAL
Intervention: FiO2 during allograft reperfusion
Number of subjects: 1255
Study 23306540 — intervention group
Group type: EXPERIMENTAL
Intervention: Single lung transplant
Number of subjects: 1255
Study 23306540 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of cardiopulmonary bypass
Number of subjects: 1255
Study 23306540 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight recipient body mass index
Number of subjects: 1255
Study 23306540 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese recipient body mass index
Number of subjects: 1255
Study 23306540 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative sarcoidosis
Number of subjects: 1255
Study 23306540 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative pulmonary arterial hypertension
Number of subjects: 1255
Study 23306540 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean pulmonary artery pressure
Number of subjects: 1255
Study 23306540 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 3 PGD
Number of subjects: 1255
Study 23307503 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (measured with accelerometers and self-report)
Number of subjects: 160
Study 23307503 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher total steps/day, higher PAEE, higher minutes of MPA/VPA, and higher PASE score
Number of subjects: 160
Study 23307766 — intervention group
Group type: EXPERIMENTAL
Intervention: Antivirals administered to 1041 (58%) patients; treatment was at the physician's discretion.
Number of subjects: 1799
Study 23307766 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir resistance detected in 19 patients postbaseline (17 H1N1pdm2009 [H275Y]; 2 H3N2 [R292K]).
Number of subjects: 1799
Study 23307766 — intervention group
Group type: EXPERIMENTAL
Intervention: All seasonal H1N1 strains were genotypically (H275Y) and phenotypically resistant to oseltamivir.
Number of subjects: 1799
Study 23307766 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutation-specific (MS) RT-PCR detected resistance to oseltamivir in 19 patients postbaseline.
Number of subjects: 1799
Study 23307766 — intervention group
Group type: EXPERIMENTAL
Intervention: No emergent resistance was found in influenza B infections.
Number of subjects: 1799
Study 23307953 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen treatment
Number of subjects: 16
Study 23307953 — intervention group
Group type: COMPARATOR
Intervention: Ambient air or pure oxygen-enriched air (without oxygen supplementation)
Number of subjects: 16
Study 23308140 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG SUVmax <6.6
Number of subjects: 40
Study 23311614 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers (AA females)
Number of subjects: 56466
Study 23311614 — intervention group
Group type: COMPARATOR
Intervention: Former/never smokers (AA females)
Number of subjects: 56466
Study 23311614 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers (EA females)
Number of subjects: 56466
Study 23311614 — intervention group
Group type: COMPARATOR
Intervention: Former/never smokers (EA females)
Number of subjects: 56466
Study 23311764 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood concentrations of ACTH, cortisol, fT3, and epinephrine in infants developing TTN
Number of subjects: 2
Study 23311764 — intervention group
Group type: COMPARATOR
Intervention: Comparison group without respiratory distress
Number of subjects: 2
Study 23312124 — intervention group
Group type: EXPERIMENTAL
Intervention: Δ melatonin concentration at 1 hour after the operation
Number of subjects: 40
Study 23312922 — intervention group
Group type: EXPERIMENTAL
Intervention: Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD)
Number of subjects: 67
Study 23312922 — intervention group
Group type: COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 67
Study 23313183 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' estimated maximum walking distance (MWD)
Number of subjects: 60
Study 23313183 — intervention group
Group type: EXPERIMENTAL
Intervention: Corridor maximum walking distance (MWD)
Number of subjects: 60
Study 23313183 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill maximum walking distance (MWD)
Number of subjects: 60
Study 23313183 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' estimated MWD vs. corridor MWD
Number of subjects: 60
Study 23313183 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' estimated MWD vs. treadmill MWD
Number of subjects: 60
Study 23313183 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' estimated MWD vs. WIQ total score
Number of subjects: 60
Study 23313183 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' estimated MWD vs. WIQ distance score
Number of subjects: 60
Study 23313183 — intervention group
Group type: EXPERIMENTAL
Intervention: Corridor MWD vs. WIQ distance score
Number of subjects: 60
Study 23313225 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum hVEGF concentration measured 24 hours after admission
Number of subjects: 104
Study 23313225 — intervention group
Group type: EXPERIMENTAL
Intervention: First measurement of serum hVEGF concentration
Number of subjects: 104
Study 23313225 — intervention group
Group type: EXPERIMENTAL
Intervention: Second measurement of serum hVEGF concentration
Number of subjects: 104
Study 23314403 — intervention group
Group type: EXPERIMENTAL
Intervention: Older group (age > 50)
Number of subjects: 79
Study 23314403 — intervention group
Group type: COMPARATOR
Intervention: NP-impaired group
Number of subjects: 79
Study 23314553 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin ultra-sensitive (copeptin-us) ≥14 pmol/L and hs-cTnT ≥0.014 µg/L
Number of subjects: 306
Study 23314553 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin ultra-sensitive (copeptin-us) <14 pmol/L and hs-cTnT <0.014 µg/L
Number of subjects: 306
Study 23314553 — intervention group
Group type: COMPARATOR
Intervention: hs-cTnT ≥0.014 µg/L alone
Number of subjects: 306
Study 23314553 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin ultra-sensitive (copeptin-us) ≥14 pmol/L added to hs-cTnT
Number of subjects: 306
Study 23315320 — intervention group
Group type: EXPERIMENTAL
Intervention: BDG and PCR assays
Number of subjects: 0
Study 23315320 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonculture tests (Mannan/anti-mannan IgG, β-D-glucan, PCR)
Number of subjects: 0
Study 23315320 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonculture tests
Number of subjects: 0
Study 23315343 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose acetylsalicylic acid (75-325 mg)
Number of subjects: 340
Study 23315343 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose acetylsalicylic acid experienced patients
Number of subjects: 340
Study 23315343 — intervention group
Group type: COMPARATOR
Intervention: Low-dose acetylsalicylic acid naïve patients
Number of subjects: 340
Study 23315343 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 340
Study 23315371 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate II devices (86 patients, 57%)
Number of subjects: 150
Study 23315371 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (no control group mentioned)
Number of subjects: 150
Study 23315599 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 60
Study 23315905 — intervention group
Group type: EXPERIMENTAL
Intervention: Deficient 25(OH)D levels (<30 nmol/L)
Number of subjects: 4418
Study 23315905 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate 25(OH)D levels (30-49.9 nmol/L)
Number of subjects: 4418
Study 23315905 — intervention group
Group type: EXPERIMENTAL
Intervention: High 25(OH)D levels (>100 nmol/L)
Number of subjects: 4418
Study 23316287 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic lesions
Number of subjects: 78
Study 23316287 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic plaques
Number of subjects: 78
Study 23316287 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic patients
Number of subjects: 78
Study 23316287 — intervention group
Group type: EXPERIMENTAL
Intervention: Human aortic smooth muscle cell culture stimulated by TNF-α
Number of subjects: 78
Study 23316287 — intervention group
Group type: EXPERIMENTAL
Intervention: Human aortic smooth muscle cell culture stimulated by lipopolysaccharide
Number of subjects: 78
Study 23316287 — intervention group
Group type: EXPERIMENTAL
Intervention: Human aortic smooth muscle cell culture stimulated by lipoteichoic acid
Number of subjects: 78
Study 23316326 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased plasma fibulin-1 levels
Number of subjects: 125
Study 23316779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of CA4P at a dose of 27 or 36 mg/m2 for 4 consecutive weeks
Number of subjects: 8
Study 23316779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of CA4P
Number of subjects: 8
Study 23318482 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesogaberan (AZD3355) as an add-on to PPI therapy
Number of subjects: 661
Study 23318482 — intervention group
Group type: COMPARATOR
Intervention: PPI therapy
Number of subjects: 661
Study 23320604 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose [90Y-DOTA]-TOC (median: 2.4 GBq/cycle)
Number of subjects: 359
Study 23320604 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate dose [90Y-DOTA]-TOC (median: 3.3 GBq/cycle)
Number of subjects: 359
Study 23320604 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose [90Y-DOTA]-TOC (median: 6.7 GBq/cycle)
Number of subjects: 359
Study 23320866 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight children
Number of subjects: 151
Study 23320866 — intervention group
Group type: COMPARATOR
Intervention: Normal weight children
Number of subjects: 151
Study 23320866 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (overweight and normal weight)
Number of subjects: 151
Study 23320927 — intervention group
Group type: EXPERIMENTAL
Intervention: huKS-IL2 (3.0 mg/m2 IV continuous infusion over 4 hours on days 2, 3, and 4) with cyclophosphamide (300 mg/m2 on day 1)
Number of subjects: 27
Study 23320927 — intervention group
Group type: EXPERIMENTAL
Intervention: huKS-IL2 (various doses) with cyclophosphamide (300 mg/m2)
Number of subjects: 27
Study 23320927 — intervention group
Group type: EXPERIMENTAL
Intervention: huKS-IL2 with cyclophosphamide
Number of subjects: 27
Study 23321252 — intervention group
Group type: EXPERIMENTAL
Intervention: YM155 alone
Number of subjects: 0
Study 23321252 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of YM155 and alemtuzumab
Number of subjects: 0
Study 23321252 — intervention group
Group type: COMPARATOR
Intervention: Alemtuzumab alone
Number of subjects: 0
Study 23321258 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperdiploidy >50 chromosomes (HD>50)
Number of subjects: 541
Study 23321258 — intervention group
Group type: EXPERIMENTAL
Intervention: Modal number of chromosomes (MNC) groups: 51-53, 54-57, 58-66
Number of subjects: 541
Study 23321258 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA index (DI) subgroups: < 1.16, ≥1.16-<1.24, ≥1.24
Number of subjects: 541
Study 23321258 — intervention group
Group type: EXPERIMENTAL
Intervention: Karyotype assessment for patients with 58-66 chromosomes
Number of subjects: 541
Study 23321489 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro fertilisation (IVF)
Number of subjects: 23498
Study 23321489 — intervention group
Group type: COMPARATOR
Intervention: Natural pregnancies
Number of subjects: 23498
Study 23321953 — intervention group
Group type: EXPERIMENTAL
Intervention: RAD001 (everolimus) 70 mg administered orally on days 1 and 7 of a 3+7 daunorubicin+cytarabine chemotherapy regimen
Number of subjects: 28
Study 23321953 — intervention group
Group type: EXPERIMENTAL
Intervention: RAD001 (everolimus) 70 mg
Number of subjects: 28
Study 23321953 — intervention group
Group type: EXPERIMENTAL
Intervention: RAD001 (everolimus)
Number of subjects: 28
Study 23324207 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian hierarchical model for estimation and outlier detection
Number of subjects: 0
Study 23324207 — intervention group
Group type: EXPERIMENTAL
Intervention: Center characteristics (number of subjects enrolled, geographical location, learning over time, nitrous oxide, temporary clipping use)
Number of subjects: 0
Study 23324207 — intervention group
Group type: EXPERIMENTAL
Intervention: Subject and disease characteristics
Number of subjects: 0
Study 23324524 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol phenylbutyrate (GPB)
Number of subjects: 15